Search results
Showing 8451 to 8500 of 8900 results
This guidance has been updated and replaced by NICE HealthTech guidance 643.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with cystic fibrosis see our guideline on diagnosing and managing cystic fibrosis and for people with COVID-19 see our guideline on managing COVID-19.
27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
COVID-19 rapid guideline: children and young people who are immunocompromised (NG174)
27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For children and young people with COVID-19 see our guideline on managing COVID-19.
COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital (NG173)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with chronic kidney disease see our guideline on assessing and managing chronic kidney disease and for people with COVID-19 see our guideline on managing COVID-19.
COVID-19 rapid guideline: acute kidney injury in hospital (NG175)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guideline on renal replacement therapy and conservative management and for people with COVID-19 see our guideline on managing COVID-19.
COVID-19 rapid guideline: arranging planned care in hospitals and diagnostic services (NG179)
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) (NG200)
This guideline has been withdrawn. VITT is associated with the COVID-19 Vaccine AstraZeneca, which is no longer available from the NHS. For people with COVID-19, see our guideline on managing COVID-19.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)
September 2023: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
May 2022: This guidance has been withdrawn. For the latest guidance, see the UK Kidney Association’s recommendations for minimising the risk of transmission of COVID-19 in adult haemodialysis units. See also NICE's guideline on managing COVID-19.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.
COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing and managing COPD in over 16s and for people with COVID-19 see our guideline on managing COVID-19.
This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.
This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.
This guidance has been updated and replaced by NICE indicator 276.
Diabetes: statins for primary prevention of CVD (40 years and over) (IND183)
This guidance has been updated and replaced by NICE indicator 275.
Diabetes: statins for primary prevention of CVD (T2DM and 10% risk) (IND182)
This guidance has been updated and replaced by NICE indicator 274.
Atrial fibrillation: pulse rhythm assessment in people at risk (IND168)
This indicator has been withdrawn following National Screening Committee recommendations and ongoing research.
Weight management: BMI calculation in preceding 5 years (IND167)
This indicator has been withdrawn following discussions with the National Screening Committee.
This guidance has been updated and replaced by NICE indicator 277.
This indicator has been updated and replaced by NICE indicator 287.
Weight management: BMI recording (long-term conditions) (IND151)
This indicator has been updated and replaced by NICE indicator 320.
Diabetes: blood pressure (without moderate or severe frailty) (IND236)
This indicator has been updated and replaced by NICE indicator 249.
Diabetes: annual psychological assessment (children) (IND57)
This indicator has been updated and replaced by NICE indicator 313 and NICE indicator 314.
This indicator has been updated and replaced by NICE indicator 312.
This indicator has been updated and replaced by NICE indicator 310 and NICE indicator 311.
This indicator has been updated and replaced by NICE indicator 308 and NICE indicator 309.
This indicator has been updated and replaced by NICE indicator 306 and NICE indicator 307.
This indicator has been updated and replaced by NICE indicator 304 and NICE indicator 305.
This indicator has been updated and replaced by NICE indicator 300 and NICE indicator 301.
This indicator has been updated and replaced by NICE indicator 302 and NICE indicator 303.
This indicator has been updated and replaced by NICE indicator 298 and NICE indicator 299.
This indicator has been updated and replaced by NICE indicator 296 and NICE indicator 297.
Cardiovascular disease prevention: cholesterol treatment target (secondary prevention) (IND268)
This indicator has been updated and replaced by NICE indicator 278.
This indicator has been updated and replaced by NICE indicator 322.
Multiple long-term conditions: falls prevention advice (IND209)
This indicator has been removed following the publication of NICE guideline NG249.
This indicator has been updated and replaced by NICE indicator 317.
This indicator has been updated and replaced by NICE indicator 317.